Clinical diagnosis and management of Alzheimer's disease

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

AD is the most common dementing illness, and its prevalence in the United States is expected to almost double over the next 25 years. Further increases in prevalence are expected to continue after that point. Diagnosis is currently based on history and clinical signs and symptoms. Routine workup should include evaluation for vascular dementia, depression, neurosyphilis, vitamin B 12 deficiency, as well as routine screening laboratory tests. Advances in imaging techniques may improve the ability to diagnose AD before it becomes clinically apparent and may allow for monitoring of AD progression. Currently there are no medications that alter the underlying disease process of AD. Disease-modifying strategies are an active area of research and it is hoped that disease-modifying agents will be available in the near future. FDA-approved medications for the treatment of AD include three cholinesterase inhibitors and one NMDA receptor modulator. The cholinesterase inhibitors should be used early and continuously through the illness. These agents do not have significant differences in terms of efficacy. The NMDA receptor modulator is only indicated for moderate to severe AD. All of these agents produce only modest benefits. Behavioral problems associated with dementia should be managed to the fullest extent possible with nonpharmacologic interventions. If nonpharmacologic interventions fail, atypical antipsychotics and SSRIs can be given a trial. Use of atypical antipsychotics carry risks for diabetes, stroke, and death. As AD is a progressive illness, the use of atypical antipsychotics and SSRIs should be periodically reassessed to evaluate their continued usefulness. Appendix 1 provides a list of Web sites that contain additional information about AD.

Original languageEnglish (US)
Pages (from-to)767-777
Number of pages11
JournalNeuroimaging Clinics of North America
Volume15
Issue number4
DOIs
StatePublished - Nov 2005

Fingerprint

Antipsychotic Agents
Alzheimer Disease
Cholinesterase Inhibitors
N-Methyl-D-Aspartate Receptors
Neurosyphilis
Vitamin B 12 Deficiency
Vascular Dementia
Aptitude
Signs and Symptoms
Dementia
History
Stroke
Depression
Research
Problem Behavior

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Clinical Neurology
  • Radiological and Ultrasound Technology

Cite this

Clinical diagnosis and management of Alzheimer's disease. / Husain, Mustafa M.; Garrett, Robert K.

In: Neuroimaging Clinics of North America, Vol. 15, No. 4, 11.2005, p. 767-777.

Research output: Contribution to journalArticle

@article{17e6205640e04fb8bcff3d1cbb8c24be,
title = "Clinical diagnosis and management of Alzheimer's disease",
abstract = "AD is the most common dementing illness, and its prevalence in the United States is expected to almost double over the next 25 years. Further increases in prevalence are expected to continue after that point. Diagnosis is currently based on history and clinical signs and symptoms. Routine workup should include evaluation for vascular dementia, depression, neurosyphilis, vitamin B 12 deficiency, as well as routine screening laboratory tests. Advances in imaging techniques may improve the ability to diagnose AD before it becomes clinically apparent and may allow for monitoring of AD progression. Currently there are no medications that alter the underlying disease process of AD. Disease-modifying strategies are an active area of research and it is hoped that disease-modifying agents will be available in the near future. FDA-approved medications for the treatment of AD include three cholinesterase inhibitors and one NMDA receptor modulator. The cholinesterase inhibitors should be used early and continuously through the illness. These agents do not have significant differences in terms of efficacy. The NMDA receptor modulator is only indicated for moderate to severe AD. All of these agents produce only modest benefits. Behavioral problems associated with dementia should be managed to the fullest extent possible with nonpharmacologic interventions. If nonpharmacologic interventions fail, atypical antipsychotics and SSRIs can be given a trial. Use of atypical antipsychotics carry risks for diabetes, stroke, and death. As AD is a progressive illness, the use of atypical antipsychotics and SSRIs should be periodically reassessed to evaluate their continued usefulness. Appendix 1 provides a list of Web sites that contain additional information about AD.",
author = "Husain, {Mustafa M.} and Garrett, {Robert K.}",
year = "2005",
month = "11",
doi = "10.1016/j.nic.2005.09.005",
language = "English (US)",
volume = "15",
pages = "767--777",
journal = "Neuroimaging Clinics of North America",
issn = "1052-5149",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Clinical diagnosis and management of Alzheimer's disease

AU - Husain, Mustafa M.

AU - Garrett, Robert K.

PY - 2005/11

Y1 - 2005/11

N2 - AD is the most common dementing illness, and its prevalence in the United States is expected to almost double over the next 25 years. Further increases in prevalence are expected to continue after that point. Diagnosis is currently based on history and clinical signs and symptoms. Routine workup should include evaluation for vascular dementia, depression, neurosyphilis, vitamin B 12 deficiency, as well as routine screening laboratory tests. Advances in imaging techniques may improve the ability to diagnose AD before it becomes clinically apparent and may allow for monitoring of AD progression. Currently there are no medications that alter the underlying disease process of AD. Disease-modifying strategies are an active area of research and it is hoped that disease-modifying agents will be available in the near future. FDA-approved medications for the treatment of AD include three cholinesterase inhibitors and one NMDA receptor modulator. The cholinesterase inhibitors should be used early and continuously through the illness. These agents do not have significant differences in terms of efficacy. The NMDA receptor modulator is only indicated for moderate to severe AD. All of these agents produce only modest benefits. Behavioral problems associated with dementia should be managed to the fullest extent possible with nonpharmacologic interventions. If nonpharmacologic interventions fail, atypical antipsychotics and SSRIs can be given a trial. Use of atypical antipsychotics carry risks for diabetes, stroke, and death. As AD is a progressive illness, the use of atypical antipsychotics and SSRIs should be periodically reassessed to evaluate their continued usefulness. Appendix 1 provides a list of Web sites that contain additional information about AD.

AB - AD is the most common dementing illness, and its prevalence in the United States is expected to almost double over the next 25 years. Further increases in prevalence are expected to continue after that point. Diagnosis is currently based on history and clinical signs and symptoms. Routine workup should include evaluation for vascular dementia, depression, neurosyphilis, vitamin B 12 deficiency, as well as routine screening laboratory tests. Advances in imaging techniques may improve the ability to diagnose AD before it becomes clinically apparent and may allow for monitoring of AD progression. Currently there are no medications that alter the underlying disease process of AD. Disease-modifying strategies are an active area of research and it is hoped that disease-modifying agents will be available in the near future. FDA-approved medications for the treatment of AD include three cholinesterase inhibitors and one NMDA receptor modulator. The cholinesterase inhibitors should be used early and continuously through the illness. These agents do not have significant differences in terms of efficacy. The NMDA receptor modulator is only indicated for moderate to severe AD. All of these agents produce only modest benefits. Behavioral problems associated with dementia should be managed to the fullest extent possible with nonpharmacologic interventions. If nonpharmacologic interventions fail, atypical antipsychotics and SSRIs can be given a trial. Use of atypical antipsychotics carry risks for diabetes, stroke, and death. As AD is a progressive illness, the use of atypical antipsychotics and SSRIs should be periodically reassessed to evaluate their continued usefulness. Appendix 1 provides a list of Web sites that contain additional information about AD.

UR - http://www.scopus.com/inward/record.url?scp=31544455281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31544455281&partnerID=8YFLogxK

U2 - 10.1016/j.nic.2005.09.005

DO - 10.1016/j.nic.2005.09.005

M3 - Article

C2 - 16443489

AN - SCOPUS:31544455281

VL - 15

SP - 767

EP - 777

JO - Neuroimaging Clinics of North America

JF - Neuroimaging Clinics of North America

SN - 1052-5149

IS - 4

ER -